PURPOSE: Recent studies have demonstrated the relevance of (18)F-FDG uptake as an independent prognostic factor for recurrence of operable non-small cell lung cancer (NSCLC). This corresponds with the experimental finding that FDG uptake correlates with the proliferative activity of tumour cells (Higashi et al., J Nucl Med 2000;41:85-92). On the basis of these observations, we studied the influence of FDG uptake on prognosis and occurrence of distant metastases in patients with advanced NSCLC. METHODS: One hundred and fifty-nine patients with NSCLC of UICC stage IIIA or IIIB were included in the study. In all patients, neoadjuvant treatment was planned to achieve operability. FDG PET was performed as an additional staging procedure prior to the initiation of therapy. Clinical outcome data in terms of overall survival, disease-free survival and incidence of distant metastases could be obtained for 137 patients and were correlated with the average standardised uptake value of the tumour (SUV(avg)). Furthermore, other factors influencing SUV(avg) and patient outcome (histological tumour type, grading, UICC stage, tumour size) were analysed. RESULTS: SUV(avg) was significantly influenced by tumour histology, UICC stage and tumour size. No significant difference could be shown for grading. In 38 out of the 159 patients (24%), FDG PET revealed previously unsuspected distant metastases. The incidence of distant metastases significantly correlated with SUV(avg). Overall survival tended to decrease with increasing SUV(avg); however, significance was only reached when a cut-off of 12.0 was applied (p=0.05). CONCLUSION: FDG uptake is an independent prognostic factor in patients with UICC stage III NSCLC, although less distinctively so than has been reported for stage I/II tumours.
PURPOSE: Recent studies have demonstrated the relevance of (18)F-FDG uptake as an independent prognostic factor for recurrence of operable non-small cell lung cancer (NSCLC). This corresponds with the experimental finding that FDG uptake correlates with the proliferative activity of tumour cells (Higashi et al., J Nucl Med 2000;41:85-92). On the basis of these observations, we studied the influence of FDG uptake on prognosis and occurrence of distant metastases in patients with advanced NSCLC. METHODS: One hundred and fifty-nine patients with NSCLC of UICC stage IIIA or IIIB were included in the study. In all patients, neoadjuvant treatment was planned to achieve operability. FDG PET was performed as an additional staging procedure prior to the initiation of therapy. Clinical outcome data in terms of overall survival, disease-free survival and incidence of distant metastases could be obtained for 137 patients and were correlated with the average standardised uptake value of the tumour (SUV(avg)). Furthermore, other factors influencing SUV(avg) and patient outcome (histological tumour type, grading, UICC stage, tumour size) were analysed. RESULTS: SUV(avg) was significantly influenced by tumour histology, UICC stage and tumour size. No significant difference could be shown for grading. In 38 out of the 159 patients (24%), FDG PET revealed previously unsuspected distant metastases. The incidence of distant metastases significantly correlated with SUV(avg). Overall survival tended to decrease with increasing SUV(avg); however, significance was only reached when a cut-off of 12.0 was applied (p=0.05). CONCLUSION:FDG uptake is an independent prognostic factor in patients with UICC stage III NSCLC, although less distinctively so than has been reported for stage I/II tumours.
Authors: K Higashi; Y Ueda; M Yagishita; Y Arisaka; A Sakurai; M Oguchi; H Seki; Y Nambu; H Tonami; I Yamamoto Journal: J Nucl Med Date: 2000-01 Impact factor: 10.057
Authors: R J Hicks; V Kalff; M P MacManus; R E Ware; A Hogg; A F McKenzie; J P Matthews; D L Ball Journal: J Nucl Med Date: 2001-11 Impact factor: 10.057
Authors: R M Pieterman; J W van Putten; J J Meuzelaar; E L Mooyaart; W Vaalburg; G H Koëter; V Fidler; J Pruim; H J Groen Journal: N Engl J Med Date: 2000-07-27 Impact factor: 91.245
Authors: S M Eschmann; G Friedel; F Paulsen; W Budach; C Harer-Mouline; B M Dohmen; R Bares Journal: Eur J Nucl Med Mol Imaging Date: 2002-04-05 Impact factor: 9.236
Authors: K Higashi; Y Ueda; K Ayabe; A Sakurai; H Seki; Y Nambu; M Oguchi; H Shikata; S Taki; H Tonami; S Katsuda; I Yamamoto Journal: Nucl Med Commun Date: 2000-08 Impact factor: 1.690
Authors: N Martini; M S Bains; M E Burt; M F Zakowski; P McCormack; V W Rusch; R J Ginsberg Journal: J Thorac Cardiovasc Surg Date: 1995-01 Impact factor: 5.209
Authors: G Schmid-Bindert; Thomas Henzler; T Q Chu; M Meyer; J W Nance; U J Schoepf; D J Dinter; P Apfaltrer; R Krissak; C Manegold; S O Schoenberg; C Fink Journal: Eur Radiol Date: 2011-08-07 Impact factor: 5.315
Authors: Wouter van Elmpt; James Hamill; Judson Jones; Dirk De Ruysscher; Philippe Lambin; Michel Ollers Journal: Eur J Nucl Med Mol Imaging Date: 2011-01-11 Impact factor: 9.236
Authors: Paul T Winnard; Arvind P Pathak; Surajit Dhara; Steven Y Cho; Venu Raman; Martin G Pomper Journal: J Nucl Med Date: 2008-06 Impact factor: 10.057
Authors: Hugo J W L Aerts; Angela A W van Baardwijk; Steven F Petit; Claudia Offermann; Judith van Loon; Ruud Houben; Anne-Marie C Dingemans; Rinus Wanders; Liesbeth Boersma; Jacques Borger; Gerben Bootsma; Wiel Geraedts; Cordula Pitz; Jean Simons; Bradly G Wouters; Michel Oellers; Philippe Lambin; Geert Bosmans; Andre L A J Dekker; Dirk De Ruysscher Journal: Radiother Oncol Date: 2009-03-28 Impact factor: 6.280
Authors: Bum Soo Kim; In Joo Kim; Seong-Jang Kim; Hyun-Yeol Nam; Kyoung June Pak; Keunyoung Kim; Man Soo Yun Journal: Nucl Med Mol Imaging Date: 2010-11-12